問卷

TPIDB > Principal Investigator

Principal Investigator



更新時間:2023-09-19

陳正生Chen, cheng sheng
  • Principal Investigator
  • Clinical Trial Experience (year) 23 years 9 個月

篩選

List

5Cases

2022-07-01 - 2024-09-20

Phase III

Completed
A 6-Week, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Cariprazine in the Acute Exacerbation of Schizophrenia, with an Additional 18-Week Blinded Extension Period
  • Condition/Disease

    Schizophrenia

  • Test Drug

    Cariprazine

Participate Sites
16Sites

Not yet recruiting3Sites

Recruiting11Sites

Terminated2Sites

2017-12-15 - 2020-12-31

Phase III

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Terminated5Sites

2021-06-01 - 2026-12-31

Phase II

A Phase 2, Randomized, Double Blind, Placebo-Controlled Study of Oral EX039 as Add-on to Acetylcholine Esterase Inhibitors in Subjects with Mild Alzheimer’s Disease
  • Condition/Disease

    Mild Alzheimer Disease

  • Test Drug

    EX039

Participate Sites
4Sites

Recruiting4Sites

2016-09-30 - 2018-12-31

Phase III

A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer′s Disease Dementia (The DAYBREAK Study)
  • Condition/Disease

    Mild Alzheimer′s Disease

  • Test Drug

    LY3314814

Participate Sites
10Sites

Terminated10Sites

2013-12-18 - 2015-10-31

Phase III

A Multicenter, Randomized, Double-blind Trial to Assess the Efficacy and Safety of ASC-01 in Patients with Major Depressive Disorder
  • Condition/Disease

    Major depressive disorder

  • Test Drug

    ASC-01

Participate Sites
12Sites

Terminated12Sites